scispace - formally typeset
T

Thomas F. Lüscher

Researcher at University of Zurich

Publications -  1613
Citations -  88517

Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.

Papers
More filters
Journal ArticleDOI

Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells.

TL;DR: It is demonstrated that CTGF can also act as a growth inhibitor in human aortic smooth muscle cells at least in part by inducing apoptosis, which may be important for the formation and composition of lesions and plaque stability in atherosclerosis.
Journal ArticleDOI

Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes.

TL;DR: Together with the local expression patterns of chemokines and cytokines, the increase of TLR-4 reflects a concerted activation of this inflammatory pathway at the site of coronary occlusion in ACS.
Journal ArticleDOI

Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.

TL;DR: Elevated serum testosterone levels in males and decreased estradiol levels in females are independently associated with MACE in ARVC/D, and directly influence disease pathology, determining the levels of sex hormones may be useful for risk stratification and may open a new window for preventive interventions.
Journal ArticleDOI

Losartan but Not Verapamil Inhibits Angiotensin II–Induced Tissue Endothelin-1 Increase Role of Blood Pressure and Endothelial Function

TL;DR: It is suggested that long-term treatment with Ang II modulates endothelin-1 protein expression in the rat aorta, and both antihypertensive drugs lowered blood pressure and normalized endothelial function, but only losartan prevented the increase in tissue endothelins-1 content.
Journal ArticleDOI

Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

TL;DR: The European Expert Group pointed out the major unmet need of standardization of measurements, trial design and procedural performance, and the need for high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will be able to establish incontrovertibly whether device therapies for hypertension are effective.